Fresenius medical care launches its strategy fme reignite with increased profitability aspirations, and a new capital allocation framework to further enhance value creation

Fme reignite sets the ambition to lead kidney care through exceptional patient care and innovation the company will set the new standard of care in the u.s. with the introduction of the 5008x dialysis machine and unveils launch plans profitability aspirations set for 2030 to advance to mid-teens percent industry-leading operating income1 margins fme25+ savings target expanded by eur 300 million to eur 1.05 billion by 2027 annual capex of eur 0.8 to 1.0 billion for core business to drive profitable growth and to support innovation further optimization of capital structure with lowered net leverage ratio target band of 2.5x to 3.0x commitment to return excess capital to shareholders: 30-40 percent dividend payout2 plus initial share buyback program of eur 1 billion bad homburg, germany and london , june 17, 2025 /prnewswire/ -- fresenius medical care (fme), the world's leading provider of products and services for people with kidney disease, today unveiled its new fme reignite strategy at its capital markets day in london. fme reignite centers on value creation, based on three strategic elements: reignite the core, reignite growth and innovation and reignite our culture.
FMS Ratings Summary
FMS Quant Ranking